Identifying approaches to reduce IRRs with IV amivantamab

Gilberto Lopes, Associate director for global oncology and interim chief for the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center, shared a post by Mark Wildgust, Vice President of Oncology Global Medical Affairs at Johnson and Johnson, on X:

“An important part of the job is to improve the safety and tolerance profile of innovative drugs. Thank you J and J Innovative Medicine, for the opportunity to participate in and present this study at WCLC24. Join us!”

Quoting for Mark Wildgust‘s post:

“Really proud of my J and J Innovative Medicine Oncology Global Medical Affairs team who led the worldwide SKIPPirr study to identify approaches to reduce IRRs with IV amivantamab. WCLC24 abstract below!

Preventing Infusion-Related Reactions with Intravenous Amivantamab: Primary Results from SKIPPirr, a Phase 2 Study

Authors: Gilberto Lopes, A.I. Spira, J-Y. Han, J-Y. Shih, C. Mascaux, U. Basu Roy, J. Zugazagoitia, Y.J. Kim, C-H. Chiu, S-W. Kim, E. Nadal, I. Gil-Bazo, S. Murphy, P. Mahadevia, B.G. Anderson, K. Xia, G. Wang, J.M. Bauml, M. Chioda, J. Simoes, L. Paz-Ares